[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604258":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":9,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Short Course Radiotherapy","EXPERIMENTAL","Short-course radiation therapy in pediatric patients with incurable central nervous system malignancies",[13],"Radiation: Short Course Radiotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","Participants will receive a shorter course of radiation therapy across 5 days (20 Gray in 5 fractions).",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Michael LaRiviere, MD","University of Pennsylvania","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Kelly Clark","CONTACT","267-854-5332","Kelly.Clark3@pennmedicine.upenn.edu",[32],{"facility":23,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-75.16362,39.95238,{"lat":43,"lon":42},[46,47],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100604258","short-course-radiotherapy-100604258",false,"NCT07147179","Pilot Trial of Short Course Radiotherapy for Primary or Secondary CNS Malignancies","Inclusion Criteria:\n\n* Male or female, aged 21 years or below\n* Lansky performance status \\>= 40\n* Has a diagnosis of an incurable malignancy that:\n\n  * Originates outside the brain but is metastatic to 1 or more sites within the brain, or originates and recurs within the brain. For this diagnosis to be confirmed, there must be multidisciplinary review of up to date imaging at a pediatric tumor board with unanimous consensus of intracranial relapse or metastasis. If the consensus is not unanimous, short-interval repeat imaging with subsequent unanimous consensus would be required in order for this eligibility criteria to be met\n  * Has at least 1 targetable intracranial lesion as seen on imaging\n  * Has a multidisciplinary consensus recommendation for palliative intent radiation\n* Consents to the study or has caregiver who is able to provide signed and dated informed consent. For subjects under the age of 18, a signed and dated assent form as able.\n* Patients who had prior radiation in planned treatment area are also eligible to enter the trial\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Radiotherapy for curative intent\n* Serious uncontrolled systemic or psychiatric disorders that would interfere with participation in the protocol\n* Being planned for proton radiation","ALL","21 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63],"NA","This is a single arm prospective pilot trial determining the safety of short-course radiation therapy in pediatric patients with incurable central nervous system malignancies.",[66],"Central Nervous System Cancer",[68,69],"Short Course","Radiotherapy","2026-04-29",{"date":72,"type":73},"2026-05-05","ACTUAL",{"date":75,"type":73},"2026-04-02",{"date":77,"type":60},"2027-03",{"name":5,"class":6},1]